STOCK TITAN

Cardiovascular Stock Price, News & Analysis

CSII Nasdaq

Welcome to our dedicated page for Cardiovascular news (Ticker: CSII), a resource for investors and traders seeking the latest updates and insights on Cardiovascular stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardiovascular's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardiovascular's position in the market.

Rhea-AI Summary

Cardiovascular Systems, Inc. (NASDAQ: CSII) has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System and ViperWire Advance® Coronary Guide Wire with Flex Tip. The Diamondback 360® is the leading coronary atherectomy device in the U.S., designed to treat various calcium modalities to improve stent placement and patient outcomes. This CE marking allows CSI to enter the European market, which is currently underutilized for coronary atherectomy. CEO Scott Ward emphasized the opportunity to collaborate with European physicians to enhance treatment options for patients with severe calcified coronary artery disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cardiovascular Systems, Inc. (NASDAQ: CSII) will host a live webcast of its fiscal 2021 second-quarter conference call on February 3, 2021, at 3:30 p.m. CT. The company will discuss its financial results for the quarter ending December 31, 2020. A post-market earnings release will precede the call on the same day. Investors can access the live webcast on CSI’s investor relations website and participate by registering online before the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

On January 13, 2021, Cardiovascular Systems (NASDAQ: CSII) CEO Scott Ward will participate in a fireside chat at the 23rd Annual Needham Virtual Growth Conference at 4:15 p.m. ET. Investors can access the live audio webcast and replay on the company's investor relations website. Cardiovascular Systems, based in St. Paul, Minn., specializes in innovative medical devices for vascular and coronary diseases, with a focus on its orbital atherectomy system that addresses limitations of existing treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

On November 18, 2020, Scott Ward, Chairman, President, and CEO of Cardiovascular Systems (NASDAQ: CSII), will present at the Stifel 2020 Virtual Healthcare Conference at 3:20 p.m. Eastern Time. Investors can access the live audio webcast and replay via the company’s investor relations website.

Cardiovascular Systems, based in St. Paul, is dedicated to developing innovative solutions for vascular and coronary diseases. Its orbital atherectomy system addresses limitations of existing treatments for calcified and fibrotic plaque in arterial vessels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Cardiovascular Systems, Inc. (CSII) reported fiscal Q1 2021 revenues of $60.5 million, a 6.1% decline from the previous year, but a 42% sequential increase compared to Q4 2020. Gross profit margin stood at 79.2%, with SG&A expenses decreasing by 13.8% to $40.3 million. R&D expenses fell 15.9% to $9.1 million due to halted clinical trials amid COVID-19. The company recorded a net loss of $2.1 million ($0.05 per share), an improvement from a loss of $5.8 million the previous year. Guidance for Q2 anticipates revenues between $63 million and $67 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cardiovascular Systems, Inc. (CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on November 4, 2020, at 3:30 p.m. CT. The management will discuss financial results for the quarter ending September 30, 2020, along with the financial outlook. A post-market earnings release will precede the call on the same day. Investors can access the webcast via the investor relations section of CSII’s website, and a replay will be available later that evening.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced significant findings from a retrospective study on its orbital atherectomy system presented at TCT Connect 2020. The study involved 519 patients with severely calcified coronary lesions, achieving a procedural success rate of 100% and low complication rates, such as dissection (0.4%) and perforation (0.8%). Notably, 30-day major adverse cardiac events (MACE) occurred in just 1.3% of patients. CEO Scott Ward emphasized the study's contribution to the safety and efficacy of the system in complex cases, underscoring CSI's commitment to advancing coronary artery disease treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the market cap of Cardiovascular (CSII)?

The market cap of Cardiovascular (CSII) is approximately 844.0M.
Cardiovascular

Nasdaq:CSII

CSII Rankings

CSII Stock Data

843.96M
40.69M
3.23%
89.65%
4.12%
Medical Devices
Healthcare
Link
United States
Saint Paul